Scarica l'app Stockscreener
18.95
0.37%
-0.07
Dopo l'orario di chiusura:
19.05
0.10
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER - GlobeNewswire Inc.
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
SciSparc And AutoMax Call Off Merger - Sahm
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
TEVA Stock Price and Chart — NYSE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva
Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt - Sahm
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
1.79%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):